Previous 10 | Next 10 |
BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Feb. 10, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced...
BioMarin Sells Priority Review Voucher for $110 Million PR Newswire SAN RAFAEL, Calif. , Feb. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to ...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
Credit Suisse argues that BioMarin Pharmaceutical (BMRN +0.8%), United Therapeutics (UTHR -1.0%), and Insmed Incorporated (INSM +1.6%) still carry further upside opportunities in 2022, despite their recent outperformance. While the biotech industry has witnessed a selloff in the past three mo...
BioMarin Pharmaceutical (BMRN +0.6%) reported sustained bleed control in certain patients with severe hemophilia A in a two-year analysis of a phase 3 study evaluating gene therapy valoctocogene roxaparvovec. In the study, GENEr8-1, Annualized Bleeding Rate (ABR) was ...
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February - Improved Bleed Free Rate from 32% at Basel...
Credit Suisse released a slimmed down best of the best picks list for February, with January debut Disney (NYSE:DIS) dropping out of the conviction picks completely. Credit Suisse Product Manager Andrew St. Pierre defines the "Top of the Crop" stocks as the "highest conviction combined with t...
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4 Latest Safety and Efficacy Data from Valoctocogene Roxaparvovec Studies, Larg...
BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN BIOMARIN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Fo...
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis - Annualized Bleeding Rate (ABR) Reduced by 85...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...